Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 13/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | RAB9A | P51151 | 8/20 | 0.34 |
| ▸ | NPC1 | O15118 | 7/20 | 0.34 |
| ▸ | TP53 | P04637 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5285479 | 0.79 | SMN1; SMN2 (0.37) | SMN1; SMN2KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL11363709 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL2402694 | 0.78 | EPHX1 (0.33) | SMN1; SMN2KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL26328058 | 0.73 | RAB9A (0.41) | SMN1; SMN2ALDH1A1RAB9ANPC1TP53 | |
| SCHEMBL24115347 | 0.71 | ALDH1A1 (0.32) | SMN1; SMN2KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL22911838 | 0.70 | — | — | |
| SCHEMBL25601617 | 0.69 | ALOX15 (0.33) | SMN1; SMN2KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL20231997 | 0.69 | AKR1C3 (0.36) | SMN1; SMN2KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL20294973 | 0.69 | KMT2A (0.37) | SMN1; SMN2KMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL31060521 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | SMN1; SMN2 3353/4885KMT2A 3648/4885ALDH1A1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.